SCHEMBL202763

SCHEMBL202763

CON1CCC[C@H]1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
RAB9A P51151 1/20 0.44
ACE P12821 8/20 0.41
REN P00797 3/20 0.41
LMNA P02545 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 1/20 0.41
F2 P00734 1/20 0.41
LTA4H P09960 1/20 0.41
MAPT P10636 1/20 0.41
PEPD P12955 1/20 0.41
ALOX15 P16050 1/20 0.41
PTGS1 P23219 1/20 0.41
HTR2A P28223 1/20 0.41
PTGS2 P35354 1/20 0.41
HRH1 P35367 1/20 0.41
THPO P40225 1/20 0.41
PMP22 Q01453 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26691320 1.00 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2RAB9AACEREN
SCHEMBL202764 1.00 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2RAB9AACEREN
Hydrochloric Acid SCHEMBL3924876 0.98 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2RAB9AACEREN
SCHEMBL443175 0.83 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2RAB9AACEREN
SCHEMBL443176 0.83 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2RAB9AACEREN
SCHEMBL30675399 0.82 POLB (0.47) ALDH1A1SMN1; SMN2LTA4HPEPDPOLB
SCHEMBL13017410 0.82 DPP4 (0.38) ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL3349893 0.81 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2RAB9AACEREN
SCHEMBL3349891 0.81 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2RAB9AACEREN
SCHEMBL27682627 0.80 RAB9A (0.41) ALDH1A1SMN1; SMN2RAB9AACEREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 US disclosed
CN-107873030-B 5-HT2CReceptor agonists and compositions and methods of use 艾尼纳制药公司 2021-03-19 CN disclosed
CN-210583153-U Solid preparation of medicine for treating impotence and premature ejaculation 厦门赛诺邦格生物科技股份有限公司 2020-05-22 CN disclosed
WO-2012048013-A2 PHOSPHORODIAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INJECTIONS INHIBITEX, INC. (US) 2012-04-12 WO disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed
EP-1389200-A4 SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS MERCK & CO INC (US) 2007-03-28 EP disclosed
CN-1744918-A Polymeric reagents comprising a ketone or a related functional group NEKTAR THERAPEUTICS AL CORP (US) 2006-03-08 CN disclosed
EP-1389200-A1 SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS Merck & Co., Inc. (US) 2004-02-18 EP disclosed
WO-2002074761-A1 SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 2002-09-26 WO disclosed
EP-0932619-A1 MACROCYCLIC PEPTIDES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS Ortho-McNeil Pharmaceutical, Inc. (US) 1999-08-04 EP disclosed
US-5888971-A ANTICOAGULANT ORTHO PHARMACEUTICAL CORPORATION, INC. (US) 1999-03-30 US disclosed
US-5801274-A N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 1998-09-01 US disclosed
WO-1997030080-A1 MACROCYCLIC PEPTIDES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1997-08-21 WO disclosed
US-5591891-A PEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1997-01-07 US disclosed
WO-1994017036-A1 S-LIPOPHILIC ALIPHATIC CARBONYL [N-MERCAPTOACYL-(AMINO ACID OR PEPTIDE)] COMPOUNDS AS ANTIHYPERTENSIVE AGENTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1994-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 ALDH1A1 343/4885SMN1; SMN2 3691/4885RAB9A 940/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS ALDH1A1 3370/4885SMN1; SMN2 4385/4885RAB9A 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.